Glenmark Pharma has received final USFDA approval for its Ranolazine extended-release tablets used for treatment of chronic angina. The drug Ranolazine extended-release tablets will be made available in the strengths of 500 mg and 1,000 mg.
The product is a generic version of Gilead Sciences Inc’s Ranexa extended-release tablets in the same strengths. According to market estimates, Ranexa extended-release tablets, 500 mg and 1,000 mg market (which includes brand and all available therapeutic equivalents) achieved annual sales of around USD 929 million.
Company Profile : Glenmark Pharma Ltd